BioSpace News Archive

Backed by ARCH Venture Partners and Fujifilm, as well as technology licensed from MIT, Tome is looking to create curative cell and integrative gene therapies.

Genetic metabolic diseases are conditions that disrupt an individual’s metabolism, which is the chemical process responsible for converting food into energy and eliminating toxins from the body.

SPR Therapeutics, Inc. announced the final patient was enrolled in the RESET Clinical Trial of SPRINT® PNS for the treatment of chronic low back pain.

City of Hope announced today that 23% of patients with relapsed or treatment-resistant KMT2Ar AML, ALL and mixed phenotype leukemia who took revumenib in the AUGMENT-101 multicenter clinical trial had a complete remission (CR) — the cancer went into remission with complete recovery of peripheral blood counts — or a CRh — the cancer went into remission and there was partial recovery of peripheral blood counts.

Calyxo, Inc., a medical device company developing next-generation treatment solutions for patients with kidney stones, has announced the closing of a $50 million Series D financing round led by Avidity Partners with significant participation from existing investors Questa Capital and CRG.

Ligand Pharmaceuticals Incorporated hosted an Investor and Analyst Day in New York City earlier. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance.

Johnson & Johnson announced today the first data from the Phase 3 PERSEUS study highlighting significant clinical improvement with a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet induction, consolidation regimen and doublet maintenance regimen in the treatment of transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM).

Oz-UK Ltd, the Chippenham-based contract research organization (CRO) dedicated to providing pressurized metered dose inhaler (pMDI) and liquid aerosol research and development (R&D

According to the latest research by nova one advisor, the global Biosimilars market size was exhibited at USD 22.19 billion in 2022 and it is expected to hold around USD 97.05 billion by 2032, growing at a CAGR of 15.9% from 2023 to 2032.

The global CAR T-cell therapy market size was estimated at USD 2.20 billion in 2022 and it is expected to surpass around USD 6.48 billion by 2032, poised to grow at a CAGR of 11.4% from 2023 to 2032.